Global Targeted DNA RNA Sequencing Market Size study, by Product, Workflow, Application, Technology, Type, End Use and Regional Forecasts 2022-2032

Global Targeted DNA RNA Sequencing Market is valued approximately at USD 10.12 billion in 2023 and is expected to expand at an impressive CAGR of more than 19.4% over the forecast period 2024-2032. Targeted DNA/RNA sequencing has quickly emerged as a cornerstone of precision medicine, allowing researchers and clinicians to zoom in on specific genomic and transcriptomic regions with heightened sensitivity, efficiency, and cost-effectiveness. Unlike whole-genome sequencing, this approach concentrates on relevant areas of the genome, enabling the identification of variants and expression patterns that are pivotal for diagnostics, disease surveillance, drug response profiling, and biomarker discovery. The demand for highly targeted approaches has been escalating due to the growing prevalence of rare genetic disorders, cancer, and chronic diseases where early detection and individualized therapy have proven to be game changers.

Driving the momentum of this market is a powerful mix of technological breakthroughs and clinical needs. The development of ultra-accurate NGS (Next-Generation Sequencing) platforms, coupled with robust pre-sequencing workflows and user-friendly bioinformatics tools, has drastically simplified genomic analysis while scaling up throughput. Further fueling growth is the global shift toward decentralized diagnostic testing and liquid biopsy innovations, which hinge on the high sensitivity of targeted sequencing protocols. Concurrently, governmental funding and private investments are pouring into omics-driven initiatives, particularly in oncology, pharmacogenomics, and infectious disease management, creating a fertile ecosystem for commercial innovation. Nevertheless, concerns surrounding data interpretation, high costs of sequencing infrastructure, and the need for skilled personnel may temper market expansion across low- and middle-income countries.

Major biotech and pharmaceutical players are embedding targeted sequencing workflows into their R&D pipelines to minimize attrition rates and uncover new drug targets. From probe design and target enrichment to variant annotation, companies are pushing for end-to-end, cloud-enabled platforms that ensure interoperability with electronic medical records and AI-powered analytics. The ability to process minimal sample volumes and detect low-frequency variants in cell-free nucleic acids has expanded its applicability across both research and clinical diagnostics. Additionally, research institutions are adopting hybrid-capture technologies and multiplex PCR methods to expedite discovery cycles and validate novel therapeutic hypotheses with high reproducibility.

Industry players are increasingly collaborating through public-private partnerships to enhance global access and create open-source databases for genomic insights. These collaborations aim to harmonize standards for sequencing assays, reduce the duplication of efforts, and promote regulatory alignment across borders. Moreover, the market is also witnessing the rise of specialized CROs offering customizable targeted sequencing services for niche therapeutic areas, bridging gaps for small and mid-sized biotech firms that lack in-house sequencing infrastructure. The integration of AI and machine learning into data interpretation is another transformative trend, making it possible to derive actionable insights from complex multi-omic datasets in near real-time.

Geographically, North America dominates the global landscape, fueled by a confluence of academic excellence, clinical innovation, and significant government backing through NIH and other federal programs. The U.S. leads in both the adoption and commercialization of targeted sequencing platforms across hospitals, research labs, and biopharma companies. Europe follows closely with robust investments in genomic health and favorable reimbursement structures, especially in countries like Germany and the UK. Meanwhile, Asia Pacific is anticipated to exhibit the fastest growth over the forecast period, driven by expanding research capabilities in China and India, rising awareness of genetic testing, and increasing patient-centric healthcare approaches. Latin America and the Middle East & Africa are gradually catching up through localized genomics initiatives and diagnostic infrastructure modernization.

Major market player included in this report are:
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN N.V.
• PerkinElmer, Inc.
• Roche Sequencing
• BGI Genomics Co., Ltd.
• Oxford Nanopore Technologies plc
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• PacBio (Pacific Biosciences)
• Twist Bioscience Corporation
• Genewiz (Part of Azenta Life Sciences)
• Integrated DNA Technologies (IDT)
• Eurofins Scientific

The detailed segments and sub-segment of the market are explained below:

By Product
• NGS

By Workflow
• Pre-sequencing

By Application
• Oncology
• Inherited Disease
• Infectious Disease
• Other Applications

By Technology
• Amplicon-based Sequencing
• Hybridization-based Sequencing

By Type
• Targeted DNA Sequencing
• Targeted RNA Sequencing

By End Use
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Historical Data: 2022, 2023

Base Year: 2023

Forecast Period: 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.